Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD2820 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AZD2820 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| AZD2820 | DRUG | Subcutaneous Injection in abdomen or Thigh |
| Placebo | DRUG | Subcutaneous Injection in abdomen or Thigh |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Healthy male subjects aged ≥20 - ≤45 years with suitable veins for cannulation or repeated venepuncture. * Male subjects should be willing to use barrier contraception ie, condoms...
AZD2820 is an investigational small molecule developed by AstraZeneca PLC. It has been studied in a Phase 1 clinical trial in healthy male volunteers in the United Kingdom. The specific disease or condition it is intended to treat has not been disclosed.
AZD2820 is being developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the Phase 1 trial of the compound conducted in the United Kingdom.
AZD2820 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound has not been approved by the FDA and remains investigational.
AZD2820 has been evaluated in one completed Phase 1 trial, NCT01332214, titled a study to assess the safety, tolerability and pharmacokinetics of AZD2820 after single ascending doses. The trial enrolled 90 healthy male volunteers in the United Kingdom and was placebo-controlled and randomized.
The AZD2820 Phase 1 trial NCT01332214 was a randomized, placebo-controlled, single ascending dose study. It enrolled 90 healthy male volunteers aged 20 years and older in the United Kingdom and assessed safety, tolerability and pharmacokinetics. The trial is completed.